Get started
Author

Robert Petryka

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · Hertzel C Gerstein, Helen M Colhoun, et al. · The Lancet · 3,144
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · Hertzel C Gerstein, Helen M Colhoun, et al. · The Lancet · 636
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
2016 · Séverine Vermeire, Stefan Schreiber, et al. · The Lancet · 441
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2023 · Brian G Feagan, Bruce E Sands, et al. · ˜The œLancet. Gastroenterology & hepatology · 246
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease
2013 · Satish Keshav, Tomáš Vaňásek, et al. · PLoS ONE · 134
PDF
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · ˜The œLancet. Gastroenterology & hepatology · 97
PDF
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2023 · Silvio Danese, Remo Panaccione, et al. · ˜The œLancet. Gastroenterology & hepatology · 74
PDF
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
2016 · Raja Atreya, Stuart Bloom, et al. · Journal of Crohn s and Colitis · 72
Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial
2016 · Matthieu Allez, Brett E Skolnick, et al. · Gut · 46
Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study
2017 · William J. Sandborn, Paul Rutgeerts, et al. · Journal of Crohn s and Colitis · 36
812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
2016 · Severine Vermeire, Stefan Schreiber, et al. · Gastroenterology · 11
Results of endoscopic and surgical fistula treatment in oesophagointestinal anastomosis after gastrectomy.
2015 · Tomasz Miłek, Piotr Ciostek, et al. · Videosurgery and Other Miniinvasive Techniques · 6
PDF
Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the Phase 2 FITZROY study
2016 · Séverine Vermeire, Stefan Schreiber, et al. · 5
OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
2017 · S. Vermeire, S. Schreiber, et al. · Journal of Crohn s and Colitis · 4
The Use of Interventional Radiology Techniques in the Treatment of Pancreatic Fistula
2016 · Tomasz Miłek, Krzysztof Baranowski, et al. · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · 4
Mo1213 Efficacy and Safety of NNC0142-0002, a Novel Human Monoclonal Antibody Targeting NKG2D: a Randomized, Double-Blind, Single-Dose Phase 2 Trial in Patients With Crohn's Disease
2014 · Matthieu Allez, Robert Petryka, et al. · Gastroenterology · 4
PDF
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial
2026 · Anita Afzali, Silvio Danese, et al. · Inflammatory Bowel Diseases · 3
827 Phase IIA, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Crohn's Disease
2015 · William J. Sandborn, Paul J. Rutgeerts, et al. · Gastroenterology · 3
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohnʼs disease trial
2008 · P Bekker, R Petryka, et al. · Inflammatory Bowel Diseases · 3
Mo1778 The Toll-Like-Receptor 9 Agonist DIMS0150 Demonstrates Therapeutic Efficacy for the Patient Reported Outcome Measures PRO-2 and Clinpro in Moderate to Severe Active Ulcerative Colitis
2016 · Raja Atreya, Stuart Bloom, et al. · Gastroenterology · 2
Multiple orifices are better than single in the endoscopic treatment of pancreatic pseudocysts
2014 · Tomasz Miłek, Piotr Ciostek, et al. · The Turkish Journal of Gastroenterology · 2
Preliminary Results of the use of Self-Expanding Nitinol Stents in Inoperable Gastrointestinal Cancers
2010 · Tomasz Miłek, Piotr Ciostek, et al. · Polish Journal of Surgery · 2
Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study
2017 · Severine Vermeire, Stefan Schreiber, et al. · Gastroenterology · 1
Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn’s Disease
2017 · Geert R. D'Haens, Stefan Schreiber, et al. · Gastroenterology · 1
Works count: 34
Citation count: 5,109
H-index: 11
I10-index: 12
Year
Topic
Type